5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid | 183550-78-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid
• 英文别名: 5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxylic acid
• CAS: 183550-78-9
• 化学式: C₁₆H₁₁NO₄
• 分子量: 281.268
• InChiKey: SSWNADJOAOFVSB-UHFFFAOYSA-N

物化性质

• 沸点：
  442.4±45.0 °C(Predicted)
• 密度：
  1.413±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid 在 氯化亚砜 、 对甲苯磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 19.5h， 生成 N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxybutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
  参考文献：
  名称：

  Enantioselective synthesis of an axially chiral 1,7-naphthyridine-6-carboxamide derivative having potent antagonist activity at the NK1 receptor

  摘要：

  一种新的高效 NK1 拮抗剂 (aR,9R)-3 [(aR,9R)-7-[3,5-双(三氟甲基)苄基]-8,9,10,11-四氢-9-甲基-5-(4-甲基苯基)-7H-[1、6,13-二酮]，通过手性中间体 6b 的环化反应，以良好的收率合成了异丙二astereoselectively。

  DOI：

  10.1039/a805333b
• 作为产物：
  描述：

  3-(4-甲基苯甲酰基)吡啶-2-羧酸 在 盐酸 、 氯化亚砜 、 sodium hydride 、 溶剂黄146 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 5.5h， 生成 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid
  参考文献：
  名称：

  Axially Chiral 1,7-Naphthyridine-6-carboxamide Derivatives as Orally Active Tachykinin NK₁ Receptor Antagonists:  Synthesis, Antagonistic Activity, and Effects on Bladder Functions

  摘要：

  Cyclic analogues of N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide (1) having a 6-9-membered ring (6-9) were synthesized and evaluated for NK1 antagonistic activities. The 8-membered ring compound with a beta-methyl group at the C-(9)-position, (aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,-11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-di-one [(aR,9R)-8b], was atropodiastereoselectively synthesized by cyclization of a chiral intermediate, 10g. On the other hand, the 7-membered ring compound with a beta-methyl group at the C-(9)-position [(9S)-7b] was obtained as an equilibrium mixture of atropisomers with a ratio of ca. 3:2 in solution at room temperature (measured by NMR in CDCl3). Compounds (9S)-7b and (aR,9R)-8b exhibited excellent antagonistic activities both in vitro [IC50 (inhibition of [I-125]BH-SP binding in human IM-9 cells) = 0.28 and 0.45 nM, respectively] and in vivo (iv and po). Significantly, the in vitro activity of (aR,9R)-8b was ca. 750-fold higher than that of its enantiomer (aS,9S)-8b, ca. 40-fold higher than its atropisomer (aS,9R)-8b, and ca. 20-fold higher than its diastereomer (aR,9S)-8b. The structure-activity relationships in this series, along with the X-ray analysis of (aR,9R)-8b, indicated that the stereochemistry around the -C-(6)(=O)-N-(7)-CH2Ar moiety is important for NK1 receptor recognition. The NK1 antagonists showed effects on bladder functions in guinea pigs upon intravenous injection: i.e., the antagonists increased the shutdown time of distension-induced rhythmic bladder contractions and the bladder volume threshold, and the effects on the shutdown time were found to correlate well with the NK1 antagonistic activities. Compound (aR,9R)-8b has been identified as a potential clinical candidate for the treatment of bladder function disorders.

  DOI：

  10.1021/jm990220r
• 作为试剂：
  描述：

  N-[3,5-bis(trifluoromethyl)benzyl]-7-(3-chloropropyl)-7,8-dihydro-5-(4-methylphenyl)-8-oxo-6-pyrido[3,4-b]pyridine carboxamide 、 3,5-双(三氟甲基)苄胺 以 7-carboxymethyl-7,8-dihydro-5-(4-methylphenyl)-8-oxo-6-pyrido[3,4-b] pyridine carbonitrile 、 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid 为溶剂， 生成 N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxamide
  参考文献：
  名称：

  Heterocyclic compounds, their production and use

  摘要：

  一种由以下通式表示的化合物：1，其中环M为杂环环，其中—X═Y<为—N═C<、—CO—N<或—CS—N<之一；Ra和Rb彼此连接形成环A，或者它们相同或不同，独立地表示氢原子或环M上的取代基；环A和环B独立地表示可任选取代的碳环或杂环环，条件是至少一个为可任选取代的杂环环；环C为可任选取代的碳环或杂环环；环Z为可任选取代的含氮杂环环；n为1至6的整数，或其盐在体外具有速激肽受体拮抗活性，并可用于预防或治疗抑郁症、焦虑症、双相情感障碍或精神病。

  公开号：

  US20020132817A1

文献信息

• Cyclic compounds, their prudiction and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05770590A1

  公开（公告）日：1998-06-23

  Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Rng C is optionally substituted homocyclic or heterocyclic ring; Rng Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has anexcellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

  具有以下通式的新化合物或其盐：##STR1##其中，环M是一个具有--N.dbd.C<、--CO--N<或--CS--N<作为部分结构--X . . . Y<的杂环环；R.sup.a和R.sup.b相互连接形成环A，或者它们相同或不同，独立地代表氢原子或环M上的取代基；环A和环B独立地代表可选择性取代的碳环或杂环，其中至少有一个是可选择性取代的杂环；环C是可选择性取代的碳环或杂环；环Z是可选择性取代的环；n代表1至6的整数，或其盐，具有优异的速激肽受体拮抗作用，以及它们的制备方法和药物组合物。
• Cyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05786352A1

  公开（公告）日：1998-07-28

  Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, and at least one of them is optionally substituted heterocyclic ring; Ring C is optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted ring; and n represents an integer of from 1 to 6, or a salt thereof, which has an excellent tachykinin receptor antagonistic effect, and their production, and pharmaceutical compositions.

  以下是通用式或其盐的新化合物。其中环M是具有-N=C-, -CO-N或-CS-N的部分结构--X...Y的杂环，R.sup.a和R.sup.b相互结合形成环A，或者它们相同或不同且分别独立地表示环M上的氢原子或取代基；环A和环B分别表示可选取代的同环或异环，其中至少一个是可选取代的异环；环C是可选取代的同环或异环；环Z是可选取代的环；n表示1至6的整数，或其盐，具有优异的Tachykinin受体拮抗作用，以及它们的制备和制药组合物。
• DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1145714A1

  公开（公告）日：2001-10-17

  The present invention relates to a medicine which comprises a compound (I) of the formula: [wherein the ring M is a heterocylic ring having -N=C<, -CO-N< or -CS-N< as a partial structure ―X=Y〈, Ra and Rb are bound to each other to form the ring A, or they are the same or different each representing a hydrogen atom or a substituent on the ring M; the rings A and B each is an optionally substituted homocycle or heterocycle, and at least one of them is an optionally substituted heterocycle; the ring C is an optionally substituted homocycle or heterocycle; the ring Z is an optionally substituted nitrogen-containing heterocycle; and n is an integer of 1 to 6] or a salt thereof in combination with a drug having an emetic action. The compounds (I) or their salts are useful as anti-emetic drugs. Particularly, vomiting caused by drugs having an emetic action can be inhibited by these compounds rapidly and safely at a low dose.

  本发明涉及一种药物，该药物由式(I)化合物组成： [其中环 M 是杂环，具有-N＝C〈、-CO-N〈或-CS-N〈作为部分结构-X＝Y〈、 Ra 和 Rb 相互结合形成环 A，或者它们相同或不同，各自代表环 M 上的一个氢原子或一个取代基； 环 A 和环 B 各自是任选取代的均环或杂环，其中至少一个是任选取代的杂环； 环 C 是任选取代的均环或杂环 环 Z 是任选取代的含氮杂环；以及 n 是 1 至 6 的整数］ 或其盐与具有催吐作用的药物结合使用。 化合物 (I) 或其盐类可用作止吐药。特别是，具有催吐作用的药物引起的呕吐，可以通过这些化合物以低剂量快速安全地抑制。
• Heterocyclic compounds, their production and use as tachykinin receptor antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1184036A2

  公开（公告）日：2002-03-06

  A compound represented by the formula: wherein ring M is a heterocyclic ring wherein is one of -N=C<, -CO-N< or -CS-N<; Ra and Rb are bonded to each other to form Ring A, or they are the same or different and represent, independently, a hydrogen atom or a substituent on the Ring M; Ring A and Ring B represent, independently, an optionally substituted homocyclic or heterocyclic ring, with the proviso that at least one of them is an optionally substituted heterocyclic ring; Ring C is an optionally substituted homocyclic or heterocyclic ring; Ring Z is an optionally substituted nitrogen-containing heterocyclic ring; and n is an integer from 1 to 6, or a salt thereof has a tachykinin receptor antagonistic activity in vitro, and is useful for preventing or treating depression, anxiety, manic-depressive illness or psychopathy.

  式所代表的化合物： 其中环 M 是杂环，其中 是-N=C<、-CO-N<或-CS-N<中的一种； Ra 和 Rb 相互结合形成环 A，或者它们相同或不同，并独立地代表氢原子或环 M 上的取代基； 环 A 和环 B 独立地代表任选取代的同环或杂环，但其中至少有一个是任选取代的杂环； 环 C 是任选取代的均环或杂环； 环 Z 是任选取代的含氮杂环；以及 n 是 1 至 6 的整数，或其盐在体外具有速激肽受体拮抗活性，可用于预防或治疗抑郁症、焦虑症、躁狂抑郁症或精神病。
• Cyclic compounds, their production and use as tachykinin receptor antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0733632B1

  公开（公告）日：2003-06-04